United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$358.22 USD
+3.89 (1.10%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $358.29 +0.07 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Price, Consensus and EPS Surprise
UTHR 358.22 +3.89(1.10%)
Will UTHR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UTHR
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
Other News for UTHR
Morgan Stanley Sticks to Their Hold Rating for United Therapeutics (UTHR)
Peering Into United Therapeutics's Recent Short Interest
United Therapeutics Corp (UTHR) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...
Liquidia jumps as Supreme Court rejects United Therapeutics request for appeal in Tyvaso patent dispute
Liquidia says Supreme Court rejects United Therapeutics' petition